Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Generative artificial intelligence (AI) leans on large language models and other machine learning models to create media ...

Image source: Getty Images. With analysts' price targets broadly ranging from $11 to $40, it is still a divisive investment.

According to TipRanks, Zgutowicz has an average return of 21.4% and a 58.61% success rate on recommended stocks. Currently, the analyst consensus on Getty Images Holdings is a Strong Buy with an ...

The market experts Avinash Gorakssakar and Sumeet Bagadia share their top stock recommendations in this special segment, Pick ...

Amazon stock is increasingly seen as a reasonable value. While the company has historically traded at negative or triple-digit price-to-earnings ratios, its valuation metrics are improving. The ...

Amazon hit a new all-time high of more than $210 on Thursday, yet many on Wall Street feel it's still an unqualified buy. Of the 66 analysts who covered the stock in October, 63 of them -- or 95% -- ...

Ganesh Dongre, Senior Manager - Technical Research at Anand Rathi, believes that the Nifty index remains trapped within the ...

While many of these "Class of 2024" stock-split stocks are market-leading businesses, their outlooks can significantly differ. As we push forward into November, one unique stock-split stock stands out ...

With a huge 8.4% dividend yield, British American Tobacco throws off a lot of passive income, but there are risks to consider.

Axis Securities has a 'buy' call on Aurobindo Pharma Ltd shares with a target of Rs 1,730 and an upside potential of 24 per ...

Image source: Getty Images. Achieving a positive gross margin is just ... a potentially lucrative opportunity Ever feel like ...